TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

On November 13, 2026 TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, reported financial results for the Company’s third quarter ended September 30, 2026, and provided a corporate update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We continue to make significant progress across each of our programs. In October, we shared our first look at data from our open-label front line study of IFx-2.0 with Keytruda in patients with deep-seated metastatic Merkel cell carcinoma, which showed durable, major objective anti-tumor responses in the first three patients with all responses ongoing for more than six months," said Dr. James Bianco, President and Chief Executive Officer of TuHURA Biosciences. "Working collaboratively with the FDA, we received clearance to begin our Phase 1b study of TBS-2025, our VISTA-inhibiting antibody, in relapsed/refractory mutNPM1 acute myeloid leukemia (AML), a molecularly defined subset of AML where the presence of VISTA on leukemic cells is associated with poor response to therapy and survival."

Dr. Bianco continued, "We will have a strong presence again this year at the upcoming American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting in December with 3 poster presentations highlighting our Delta Opioid Receptor (DOR) technology. The ASH (Free ASH Whitepaper) scientific review committee recognized the importance of our discoveries of the central role the DOR plays in controlling proliferation, recruitment and immunosuppressive capabilities of MDSCs, the body’s main cell type for suppressing immune responses leading to acquired resistance to cancer immunotherapies."

"With meaningful progress having been made in each of our programs, we believe we are well positioned to deliver on several transformational potential milestones. Having continuing access to a $50mm credit facility from our largest shareholder has allowed us to fund operations in a non-dilutive manner benefiting shareholders as we continue driving towards these value-creating events," Dr. Bianco concluded.

Third Quarter and Recent Corporate Highlights:

•
Announced three poster presentations at the 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition taking place December 12-15, 2026, in New Orleans. The posters highlight research on the role of the Delta Opioid Receptor (DOR) in controlling the immunosuppressive capabilities of myeloid-derived suppressor cells (MDSCs), and the data underscore the potential therapeutic breadth of DOR technology across MDSCs, T regs and M2 macrophages.

•
Provided a first look at data from its open-label study of IFx-2.0 as an adjunctive therapy to Keytruda in first line treatment of patients with deep seated metastatic Merkel Cell Carcinoma. Preliminary results demonstrated major objective partial responses in each of the first 3 patients, constituting major objective tumor responses, which are ongoing for more than six months.

•
Received a new U.S. Patent broadening coverage for its VISTA Inhibitor, TBS-2025. The patent extends coverage to include bispecific/multi-specific antibodies across all classes of human antibodies as well as coverage for methods of treatment that extend beyond cancer, expanding into new treatment areas like autoimmune disease and infection. The patent term extends to 2042, prior to any potential patent term adjustment and/or regulatory patent term extension.

•
Received key U.S. patent for its groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) technology. The patent discloses uses beyond ADCs, including autologous or allogeneic adoptive cellular immunotherapies like CAR-T, Tregs or TIL cell therapies. The term of the patent runs through 2043 before any patent term extension.

•
Well funded to achieve clinical goals. The Parkview loan facility contributed $5.6 million in non-dilutive financing during the quarter ended September 30, 2026. This facility allows the Company to operationally proceed on all fronts while maintaining shareholder value. This facility also allows the Company to focus exclusively on operational goals.

•
Received FDA "Study May Proceed" notice and IND clearance for the evaluation of its VISTA-Inhibiting Antibody in molecularly defined subsets of AML and other blood-related cancers. The IND allows the Company to examine TBS-2025 in a Phase 1b study evaluating the safety and potential efficacy of monotherapy at different doses in patients with relapsed/refractory (r/r) mutNPM1 AML who have failed to respond to or relapsed after Menin inhibitor therapy. If TBS-2025 results in encouraging response rates during the dose-optimization stage of the study, the Company will explore with the FDA the potential expansion of the trial in consideration for the opportunity for accelerated approval.

Currently Anticipated Milestones by Program

IFx-2.0 (Innate Immune Agonist)

•
2H 2026: Expect to receive orphan drug designation in MCC
•
1H2027: Expect preliminary results from front-line study IFX-2.0 with Keytruda when administered by CT or ultrasound-guided techniques to metastatic deep seated MCC
•
2H 2027: Expect to complete enrollment in the Company’s Phase 3 registrational front-line study of IFx-2.0 as adjunctive therapy to Keytruda in advanced or metastatic MCC

TBS-2025 (VISTA inhibiting mAb)

•
2H 2026: Expect to initiate a Phase 1b/2 trial of TBS-2025 VISTA inhibiting antibody in mutNPM1 r/r AML
•
1H 2027: Expect to receive orphan drug designation in AML
•
1H 2027: Expect preliminary safety and response data for VISTA in mutated NMP1 r/r AML

MDSC Inhibitors (Bi-specific ADCs)

•
2H 2026: Presentations at ASH (Free ASH Whitepaper)
•
2H 2026: Initiation of ADC in vivo POC studies

Summary of Financial Results for the Third Quarter 2026

Cash and cash equivalents of $1.9 million at September 30, 2026. The Company received $9.2 million in gross proceeds as of September 30, 2026, on the Parkview credit facility.

Research and development expenses were $3.7 million and $5.0 million for the 3 months ended September 30, 2026, and 2025, respectively. The decrease of $1.3 million was due to lower manufacturing costs, which are expected to resume in the next quarter with the start of the TBS-2025 clinical trial material manufacturing campaign.

General and administrative (G&A) expenses were $2.0 million and $1.6 million for the 3 months ended September 30, 2026, and 2025, respectively. The increase of $0.4 million was primarily due to increases in non-cash stock compensation expense and costs associated with being a public company.

Net cash outflows from operating activities were ($18.1) million and ($22.1) million for the 9 months ended September 30, 2026, and 2025, respectively.

Net cash flows from financing activities were $16.5 million and $13.4 million for the 9 months ended September 30, 2026, and 2025, respectively.

Total common shares outstanding were approximately 65.8 million at September 30, 2026.

(Press release, TuHURA Biosciences, NOV 13, 2026, View Source [SID1234674754])

Xenetic Biosciences Reports Third Quarter 2026 Financial Results and Highlights Strategic Business Updates

On November 13, 2026 Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, reported financial results for the third quarter ended September 30, 2026, and highlighted its proposed share exchange transaction with Santersus AG ("Santersus"), which is expected to establish a Nasdaq-listed, clinical-stage company with a differentiated pipeline targeting neutrophil extracellular traps (NETs) across multiple high-value therapeutic indications.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This is a defining period for Xenetic as we work toward completing a transaction that we believe has the potential to fundamentally transform the Company’s clinical development profile and long-term value proposition," said James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic Biosciences. "Santersus is expected to bring an established clinical-stage platform, two FDA Breakthrough Device Designations and a pipeline targeting serious diseases with substantial unmet medical needs. Importantly, the proposed combined company would have multiple development programs and potential catalysts, including an ongoing pivotal sepsis study, planned advancement in lupus and an anticipated oncology clinical readout in 2027."

Mr. Parslow continued, "We believe the complementary nature of NucleoCapture and Xenetic’s DNase platform provides a differentiated opportunity to address NETs through distinct mechanisms, potentially expanding the therapeutic reach of the combined platform. Our focus remains on advancing the proposed transaction and positioning the combined organization to execute against its development priorities and build sustainable stockholder value."

Third Quarter 2026 and Recent Strategic Highlights

Initiated Clinical Evaluation of DNase I in Combination with CAR T-Cell Therapy: Announced the first patient dosed in an investigator-initiated, Phase I (NCT07361224) clinical study evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T-cell therapy in patients with large B-cell lymphoma (LBCL). The study is being conducted at Tel Aviv Sourasky University Medical Center in Israel in collaboration with PeriNess Ltd., with initial efficacy data expected in the second quarter of 2027.
Advanced Pre-Clinical Development Strategy in CAR T cell therapy: Research examines a self-reinforcing niche of therapy resistance created by extracellular chromatin and NETs released during CAR T-cell killing and its reversal by DNase I.
Announced Definitive Exchange Agreement with Santersus AG: Entered into a definitive share exchange agreement to, subject to Xenetic’s stockholder approval, acquire all of the outstanding share capital of Santersus AG in exchange for newly issued shares of Xenetic in an all-stock transaction (the "Proposed Transaction"). The Proposed Transaction is expected to create a Nasdaq-listed clinical-stage company focused on targeting neutrophil extracellular traps (NETs) across multiple therapeutic indications. After closing, the combined company is expected to continue to trade on the Nasdaq Capital Market as Santersus Bio, Inc., under new ticker symbol "SNTS".The Proposed Transaction has been unanimously approved by the Board of Directors of Santersus. Xenetic’s Board of Directors – acting on the unanimous recommendation of its independent Special Committee – has also approved the Proposed Transaction and recommends that Xenetic stockholders vote in favor of the Proposed Transaction. The Proposed Transaction is expected to close in the first quarter of 2027, subject to approval by Xenetic stockholders, the shares of Xenetic common stock issuable in the Proposed Transaction having been approved for listing on Nasdaq, the effectiveness of a resale registration statement on Form S-1 to be filed with the U.S. Securities and Exchange Commission ("SEC"), and the satisfaction or waiver of other customary closing conditions.
Summary of Financial Results for Third Quarter 2026

Royalty revenue for the three months ended September 30, 2026 decreased approximately 29% to approximately $0.7 million, compared to approximately $1.0 million for the comparable prior-year period. The decrease was primarily attributable to positive royalty adjustments recognized from certain countries during the third quarter of 2025 under the Company’s sublicense agreement with Takeda Pharmaceutical Co. Ltd.

Research and development expenses for the three months ended September 30, 2026 decreased approximately 31% to approximately $0.5 million, compared to approximately $0.8 million for the comparable prior-year period, primarily due to lower manufacturing development costs.

General and administrative expenses for the three months ended September 30, 2026 increased approximately 138% to approximately $1.9 million, compared to approximately $0.8 million for the comparable quarter of 2025. The increase was primarily attributable to higher legal and financial advisory expenses associated with the Proposed Transaction.

Net loss for the quarter ended September 30, 2026 was approximately $1.7 million, or $0.72 per basic and diluted share, compared to approximately $0.5 million, or $0.33 per basic and diluted share, for the same period in 2025.

Cash and cash equivalents totaled approximately $5.8 million as of September 30, 2026, compared to approximately $7.9 million as of December 31, 2025.

(Press release, Xenetic Biosciences, NOV 13, 2026, View Source [SID1234674755])

EpicentRx presents new clinical data at CTOS 2026

On November 12, 2026 EpicentRx reported its CEO Dr. Tony Reid will be at The Connective Tissue Oncology Society 2026 Annual Meeting taking place November 18–21, 2026, in Seoul, South Korea. New clinical data from the Phase 1/2 BETAPRIME trial will be presented in the abstract entitled: ADAPT-001 with a checkpoint inhibitor in angiosarcoma refractory to checkpoint inhibition: activity and durability of response.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Press release, EpicentRx, NOV 12, 2026, View Source [SID1234674672])

TScan Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

On November 12, 2026 TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, reported financial results for the three months ended September 30, 2026, and provided a corporate update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This quarter marked an important step in accelerating TScan’s solid tumor program. We are concentrating all our efforts on our in vivo-engineered TCR-T cell approach for solid tumor indications, where we see an opportunity to bring an exciting new treatment modality to patients in desperate need of better treatment options. Our team is working to advance our two lead candidates through preclinical development and complete the studies required to support clinical entry, with the goal of dosing our first patient by the fourth quarter of next year," said Gavin MacBeath, Ph.D., Chief Executive Officer. "At the same time, we are actively pursuing strategic partnerships to advance our heme malignancies and autoimmunity programs. We are excited about the progress we have made this year on our in vivo TCR-T candidates and look forward to sharing more of our preclinical data and FDA feedback in early 2027."

Recent Corporate Highlights

•
In September, the Company announced a strategic reorganization to prioritize its in vivo solid tumor program. TScan’s first two therapeutic candidates, one targeting PRAME and the other targeting MAGE-A4, were advanced to IND-enabling studies.
•
The Company also provided updated data in September from Cohort C of its Phase 1 ALLOHA study of TSC-101 in heme malignancies. At the time of the update, all 14 patients in Cohort C of the study showed complete donor chimerism at their last assessment, including the two patients who had previously relapsed. The Company paused further enrollment in the Phase 3 ALLOHA-2 study of TSC-101 due to insufficient capital needed to complete the trial and is actively seeking strategic partnerships. TScan remains committed to tracking the patients enrolled in Cohort C of the Phase 1 study, as well as the 7 patients who were enrolled on the treatment arm of the Phase 3 ALLOHA-2 study and the five patients enrolled on the control arm of ALLOHA-2.

Pipeline Progress and Upcoming Anticipated Milestones

Solid Tumor Program: The Company’s strategy is to treat patients with in vivo-engineered TCR-T therapy candidates, initially as singleplexed therapy and ultimately as multiplexed therapy. The Company currently has two candidates in IND-enabling studies: one targeting PRAME and the other targeting MAGE-A4.

Anticipated Milestones

•
Disclose preclinical data and FDA feedback from pre-IND meetings on TSC-303-A02 (PRAME) and TSC-302-A02 (MAGE-A4) in Q1 2027.
•
File the first IND for in vivo-engineered TCR-T for solid tumors in Q3 2027, with first patient dosed in Q4 2027.
•
Report initial Phase 1 data on in vivo-engineered TCR-T in H1 2028.

Heme Malignancies Program: TScan’s TCR-T therapy candidate, TSC-101, is designed to treat residual disease and prevent relapse in patients with heme malignancies undergoing allogeneic hematopoietic cell transplantation (HCT). TScan is currently seeking strategic partners for this program.

Anticipated Milestones

•
Share updated data on patients treated in Cohort C of the Phase 1 ALLOHA study at the upcoming 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition in Q4 2026.
Title: Phase 1 (ALLOHA) trial cohort C: TSC-101 eliminates recipient hematopoietic cells and demonstrates potential for improved outcomes in patients with AML, ALL, or MDS post-allogeneic RIC HCT

Publication Number: 4178

Presentation Date and Time: December 13, 2026, 6:00 – 8:00 pm E.T.

•
Share updated data, including >1 year of follow-up time, on Cohort C patients of the ALLOHA study, and new data, including >6 months of follow-up time, on patients enrolled in the ALLOHA-2 study, in the first half of 2027.

Autoimmunity Program: The Company has discovered novel targets for ankylosing spondylitis and other HLA-B*27-associated autoimmune disorders and is currently seeking strategic partners for this program.

Third Quarter 2026 Financial Results

Revenue: Revenue for the third quarter of 2026 was $0.6 million, compared to $2.5 million for the third quarter of 2025. The decrease was primarily due to timing of research activities pursuant to the Company’s collaboration agreement with Amgen, which was terminated in August 2026.

R&D Expenses: Research and development (R&D) expenses for the third quarter of 2026 were $25.3 million, compared to $31.7 million for the third quarter of 2025. The decrease of $6.4 million was primarily driven by a decrease in laboratory supplies, research materials, and studies due to the timing in the purchase of supplies and consumables, and decrease spend on contracted services, as well as savings in connection with the 2025 workforce reduction. R&D expenses included non-cash stock compensation expense of $1.0 million and $1.7 million for the third quarter of 2026 and 2025, respectively.

G&A Expenses: General and administrative (G&A) expenses for the third quarter of 2026 were $8.3 million, compared to $7.9 million for the third quarter of 2025. The increase of $0.5 million was primarily due to costs incurred in connection with the 2026 reorganization. G&A expenses included non-cash stock compensation expense of $1.1 million and $1.3 million for the third quarter of 2026 and 2025, respectively.

Net Loss: Net loss was $33.1 million for the third quarter of 2026, compared to $35.7 million for the third quarter of 2025, and included net interest expense of $0.1 million and net interest income of $1.3 million, respectively.

Cash Position: Cash and cash equivalents as of September 30, 2026, were $73.0 million, excluding $5.0 million of restricted cash. The Company believes that its existing cash resources will be sufficient to fund its current operating plan into the fourth quarter of 2027. The Company did not achieve certain non-covenant related milestones by June 30, 2026 as provided under its existing debt agreement. The updated cash runway therefore reflects commencement of the two-year term loan amortization beginning in the fourth quarter of 2026.

Share Count: As of September 30, 2026, the Company had 67,779,255 issued and outstanding shares of common stock, consisting of 63,502,667 shares of voting common stock and 4,276,588 shares of non-voting common stock, as well as 62,246,707 outstanding pre-funded warrants to purchase shares of voting common stock at an exercise price of $0.0001 per share. Pro forma outstanding shares, inclusive of both common stock and pre-funded warrants, were 130,025,962 as of September 30, 2026.

(Press release, TScan Therapeutics, NOV 12, 2026, View Source [SID1234674688])

Enhertu® Supplemental New Drug Application Submitted in Japan for Patients with HER2 Expressing Advanced or Recurrent Uterine Carcinosarcoma

On November 15, 2026 Daiichi Sankyo (TSE: 4568) reported it has submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for Enhertu (trastuzumab deruxtecan) for the treatment of patients with HER2 expressing (immunohistochemistry [IHC] 3+, IHC 2+ or IHC 1+) advanced or recurrent uterine carcinosarcoma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being developed and commercialized by Daiichi Sankyo in Japan.

The sNDA is based on data from the STATICE phase 2 trial, an investigator-initiated trial conducted in Japan, which was published in the Journal of Clinical Oncology. In the trial, Enhertu (5.4 mg/kg) demonstrated durable responses across levels of HER2 expression in patients with advanced or recurrent uterine carcinosarcoma previously treated with chemotherapy (including adjuvant chemotherapy). STATICE is the first prospective trial to show clinical activity with a HER2 directed medicine in this rare form of cancer.

"Patients with HER2 expressing advanced uterine carcinosarcoma in Japan face a poor prognosis, with treatment relying on chemotherapy rather than options directed at a specific molecular target," said Yuki Abe, PhD, Senior Executive Officer, Head of R&D Division in Japan and Head of Research, Daiichi Sankyo. "The durable activity demonstrated in the STATICE trial underscores the benefit of targeting HER2 with Enhertu in this difficult-to-treat cancer. If approved, Enhertu could provide an important targeted treatment option for patients with uterine carcinosarcoma in Japan."

Enhertu currently is approved in more than 50 countries/regions worldwide to treat patients with HER2 positive (IHC 3+) solid tumors who have received prior treatment and/or who have no satisfactory treatment options. In Japan, Enhertu can be considered as a treatment option for patients with HER2 positive (HER2 [ERBB2] gene amplification or IHC 3+) uterine carcinosarcoma when standard treatment is not appropriate.

Enhertu also is under review in Japan as an adjuvant treatment for patients with HER2 positive (IHC 3+ or in-situ hybridization (ISH)+) breast cancer with residual invasive disease after neoadjuvant therapy based on data from DESTINY-Breast05.

About STATICE

STATICE is a multicenter, open-label, single-arm investigator-initiated phase 2 trial evaluating the efficacy and safety of Enhertu (6.4 or 5.4 mg/kg) in patients in Japan with HER2 expressing (HER2 IHC 3+, IHC 2+ or IHC 1+) advanced or recurrent uterine carcinosarcoma who have received prior chemotherapy (including adjuvant chemotherapy). At trial initiation, Enhertu 6.4 mg/kg was administered; however, based on an assessment of risk/benefit, the dosing was modified mid-trial to 5.4 mg/kg and was determined to be the preferred dose for this patient population.

The primary endpoint of STATICE is objective response rate (ORR) as assessed by central review in patients with HER2 expressing tumors with IHC ≥ 2+. Secondary endpoints include investigator-assessed ORR in patients with HER2 expressing tumors with IHC ≥ 2+, ORR by central review and investigator assessment in patients with HER2 IHC 1+ tumors, progression-free survival (PFS), overall survival (OS) and safety. Results from STATICE were published in the Journal of Clinical Oncology.

STATICE enrolled 34 patients across seven sites in Japan. For more information about the trial, visit Japan’s University Hospital Medical Information Network.

About Uterine Carcinosarcoma

Uterine carcinosarcoma is a rare, highly aggressive form of endometrial cancer that accounts for fewer than 5% of endometrial cancer cases in Japan.1,2,3 Despite its rarity, uterine carcinosarcoma is estimated to account for approximately 15% of endometrial cancer-related deaths.3 Prognosis remains poor, with lower overall survival for uterine carcinosarcoma compared to other types of endometrial cancer and particularly poor outcomes reported following later lines of treatment in recurrent or metastatic uterine carcinosarcoma.

HER2 is a tyrosine kinase receptor protein involved in cell growth and differentiation and expressed on the surface of multiple tumor types.6 HER2 expression (IHC 3+, IHC 2+, or IHC 1+) was observed in 72.3% of patients with uterine carcinosarcoma, supporting HER2 as a potential therapeutic target.7 Pre-clinical trials evaluating HER2 targeted therapies showed promising antitumor effects, supporting the potential of HER2 as a therapeutic target in uterine carcinosarcoma.

In Japan, paclitaxel plus carboplatin chemotherapy is commonly used as systemic treatment for unresectable, advanced uterine carcinosarcoma, including recurrent disease.11,12,13 However, median disease-free survival with this regimen is less than two years and disease recurrence occurs in 57% of patients with uterine carcinosarcoma.

About Enhertu

Enhertu (trastuzumab deruxtecan; fam-trastuzumab deruxtecan-nxki in the U.S. only) is a HER2 directed ADC. Designed using the proprietary DXd ADC Technology of Daiichi Sankyo, Enhertu is the lead ADC in the oncology portfolio of Daiichi Sankyo and the most advanced program in AstraZeneca’s ADC scientific platform. Enhertu consists of a HER2 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers.

Enhertu (5.4 mg/kg) followed by THP is approved in more than five countries/regions worldwide as a neoadjuvant treatment for adult patients with HER2 positive (IHC 3+ or ISH+) stage 2 or stage 3 breast cancer based on the results from the DESTINY-Breast11 trial.

Enhertu (5.4 mg/kg) is approved in more than 35 countries/regions worldwide for the adjuvant treatment of adult patients with HER2 positive breast cancer who have residual invasive disease following neoadjuvant trastuzumab (with or without pertuzumab) and taxane-based treatment based on the DESTINY-Breast05 trial.

Enhertu (5.4 mg/kg) in combination with pertuzumab is approved in more than 40 countries/regions worldwide as a first-line treatment for adult patients with unresectable or metastatic HER2 positive (IHC 3+ or ISH+) breast cancer, as determined by a locally or regionally approved test, based on the results from the DESTINY-Breast09 trial.

Enhertu (5.4 mg/kg) is approved in more than 100 countries/regions worldwide for the treatment of adult patients with unresectable or metastatic HER2 positive (IHC 3+ or ISH+) breast cancer who have received a prior antiHER2-based regimen, either in the metastatic setting or in the neoadjuvant or adjuvant setting, and have 3 developed disease recurrence during or within six months of completing therapy based on the results from the DESTINY-Breast03 trial

Enhertu (5.4 mg/kg) is approved in more than 75 countries/regions worldwide for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 low (IHC 1+ or IHC 2+/ ISH-) or HER2 ultralow (IHC 0 with membrane staining) breast cancer, as determined by a locally or regionally approved test, that have progressed on one or more endocrine therapies in the metastatic setting based on the results from the DESTINY-Breast06 trial.

Enhertu (5.4 mg/kg) is approved in more than 100 countries/regions worldwide for the treatment of adult patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy based on the results from the DESTINY-Breast04 trial.

Enhertu (5.4 mg/kg) is approved in more than 80 countries/regions worldwide for the treatment of adult patients with unresectable or metastatic NSCLC whose tumors have activating HER2 (ERBB2) mutations, as detected by a locally or regionally approved test, and who have received a prior systemic therapy based on the results from the DESTINY-Lung02 and/or DESTINY-Lung05 trials. Continued approval in China and the U.S. for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Enhertu (6.4 mg/kg) is approved in more than 90 countries/regions worldwide for the treatment of adult patients with locally advanced or metastatic HER2 positive (IHC 3+ or IHC 2+/ISH+) gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen based on the results from the DESTINY-Gastric01, DESTINY-Gastric02 and/or DESTINY-Gastric04 trials.

Enhertu (5.4 mg/kg) is approved in more than 50 countries/regions worldwide for the treatment of adult patients with unresectable or metastatic HER2 positive (IHC 3+) solid tumors who have received prior treatment and/or have no satisfactory alternative treatment options based on efficacy results from the DESTINY-PanTumor02, DESTINY-Lung01, DESTINY-CRC02, DESTINY-PanTumor03 and/or HERALD trials. Continued approval in China and the U.S. for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

(Press release, Daiichi Sankyo, NOV 12, 2026, View Source [SID1234674707])